Loading provider…
Loading provider…
Pulmonary Disease Physician in Nashville, TN
NPI: 1144312562Primary Practice Location
VANDERBILT UNIVERSITY MEDICAL CENTER
2200 Childrens Way, Nashville, TN
Primary Employer
Spirocare DME LLC
hmpinc.net
HQ Phone
Get MD Lisa's Phone NumberMobile
Get MD Lisa's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
TN State Medical License
1996 - 2027
AL State Medical License
2020 - 2020

American Board of Internal Medicine
Pulmonary Disease
Medical College of Georgia
augusta.edu
Medical School
Until 1993
Vanderbilt University Medical Center
vumc.org
Fellowship • Pulmonary Disease and Critical Care Medicine
1996 - 1999
University of Tennessee (Nashville)
Residency • Internal Medicine
1993 - 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 94010Measurement and graphic recording of total and timed exhaled air capacity | 238 | 299 |
| 2 | 94729Measurement of lung diffusing capacity | 229 | 284 |
| 3 | 94726Determination of lung volumes using plethysmography | 135 | 156 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 63 | 68 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 58 | 89 |
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.
Authors: Jonathan Goldin, David Hotchkin, Christopher Ryerson, Jonathan Ilowite
Publication Date: 2020-09
Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real-world patient data repository.
Authors: Harrison Farber, Murali Chakinala, Ronald Oudiz
Publication Date: 2023-07
Lead Sponsor: Fernando J Martinez
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), University of Michigan, University of Virginia, Pulmonary Fibrosis Foundation, University of Washington, Three Lakes Foundation
Intervention / Treatment: DRUG: Placebo, DRUG: N-acetyl cysteine
Lead Sponsor: Galecto Biotech AB
Collaborators: Syneos Health, bioRASI, LLC
Intervention / Treatment: DRUG: Placebo, DRUG: GB0139
Lead Sponsor: FibroGen
Intervention / Treatment: DRUG: Placebo, DRUG: Sub-Study: Nintedanib, DRUG: Pamrevlumab, DRUG: Sub-Study: Pirfenidone